Evolus Inc. (EVL)
XBER 
Summary
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Evolus, Inc. ( EOLS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Rui Avelar - Chief Medical Officer and Head of Research & Development Tatjana Mitchell - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, everyone, and thank you for standing by.
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.
Evolus Inc. (EVL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Evolus Inc. ever had a stock split?
Evolus Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | David Moatazedi CEO | XBER Exchange | US30052C1071 ISIN |
| US Country | 372 Employees | - Last Dividend | - Last Split | 8 Feb 2018 IPO Date |
Overview
Evolus, Inc. operates within the performance beauty sector, focusing on the cash-pay aesthetic market across the United States, Canada, and Europe. Since its incorporation in 2012, the company has dedicated itself to offering innovative aesthetic products. With its headquarters in Newport Beach, California, Evolus has carved out a niche in the competitive beauty industry by providing alternatives for temporary improvement in the appearance of facial lines and wrinkles.
Products and Services
- Jeuveau: This proprietary formulation of 900 kilodalton purified botulinum toxin type A is specifically designed for the temporary improvement of moderate to severe glabellar lines in adults, catering to the demand for non-surgical cosmetic procedures.
- Dermal Filler Products:
- Estyme: A dermal filler product offered by Evolus, aiming to address various aesthetic concerns by smoothing out wrinkles and adding volume to facial structures.
- Evolysse: Another dermal filler in Evolus' portfolio, designed to offer patients aesthetic enhancements and corrections with a focus on natural-looking results.
